Search clinical trials for: HBV-related unresectable HCC

Total 3778 results

Tongji University
Interventional Radiology Research Group, Shanghai Radiology Society

Unknown

TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC) (TACE)

Hepatocellular Carcinoma | Hepatitis B Virus

China
Shanghai Zhongshan Hospital
Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Chang Gung Memorial Hospital

Not yet recruiting

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma (PhotonAB)

Hepatocellular Carcinoma

Taiwan
Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Zhiyong Huang
Wuhan University; Hubei Cancer Hospital; Wuhan Union Hospital, China; Renmin Hospital... and other collaborators

Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Unresectable Hepatocellular Carcinoma

China
Institute of Liver and Biliary Sciences, India

Not yet recruiting

Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

India
University of Florida
Novatek

Not yet recruiting

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

Hepatocellular Carcinoma
Chang Gung Memorial Hospital

Recruiting

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma (ProtonAB)

Hepatocellular Carcinoma Non-resectable

Taiwan
AstraZeneca

Recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)

United States
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

SIRT for Potentially Resectable HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Sirtex Medical

Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) (SIRtain)

Unresectable Hepatocellular Carcinoma (HCC) | Liver Metastases From Colorectal Cancer (mCRC)

Spain, United Kingdom, France
Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Terumo Europe N.V.

Recruiting

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) (BIOPEARL-ONE)

Hepatocellular Carcinoma Non-resectable

Belgium, Germany, Italy
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
Wan-Guang Zhang

Recruiting

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC (CCGLC-010)

Macrotrabecular Massive Hepatocellular Carcinoma

China
Xuhua Duan

Recruiting

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

HCC

China
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Replimune Inc.
Roche Pharma AG

Not yet recruiting

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recurrent Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma

United States, United Kingdom, France, Germany, Greece
Seoul National University Hospital

Recruiting

Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC

Hepatocellular Carcinoma | Malignant Biliary Obstruction

Korea, Republic of
University of Kansas Medical Center
Varian Medical Systems

Recruiting

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC (vGRID SBRT)

Liver Cancer

United States
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Beijing Shenogen Biomedical Co., Ltd

Recruiting

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP) (BESTPOP)

Hepatocellular Carcinoma

China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (Liver-NET1)

Hepatocellular Carcinoma

France
Nanfang Hospital of Southern Medical University

Not yet recruiting

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

Hepatocellular Carcinoma
Sun Yat-sen University
First People's Hospital of Foshan; Guangzhou No.12 People's Hospital

Recruiting

HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Hepatocellular Carcinoma

China
Gao-jun Teng

Recruiting

TACE With Dicycloplatin(TP21) in Unresectable HCC

Hepatocellular Carcinoma

China
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Akeso

Not yet recruiting

A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma
Akeso

Recruiting

A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Unresectable, Non-metastatic Hepatocellular Carcinoma

China
Zhejiang University

Not yet recruiting

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
National Taiwan University Hospital

Not yet recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Unresectable Hepatocellular Carcinoma | Pembrolizumab | Stereotactic Body Radiotherapy | Lenvatinib

Taiwan
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaborators

Recruiting

DEB-TACE+HAIC vs. HAIC for Large HCC

Unresectable Hepatocellular Carcinoma

China
TaiRx, Inc.

Recruiting

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Advanced Cancer

Taiwan
Shanghai Zhongshan Hospital

Recruiting

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Hepatocellular Carcinoma | Donafenib

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
Massachusetts General Hospital
Genentech, Inc.

Not yet recruiting

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

Unresectable Hepatocellular Carcinoma

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
The University of Hong Kong

Recruiting

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

HCC

Hong Kong
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC

Hepatocellular Carcinoma Non-resectable

China
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Methodist Health System

Recruiting

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

Hepatocellular Carcinoma

United States
Fudan University

Not yet recruiting

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

Search clinical trials for: HBV-related unresectable HCC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations